Results 61 to 70 of about 180,170 (299)

Multiple myeloma laboratory diagnostics made simple: practical insights and key recommendations [PDF]

Multiple myeloma is a clonal plasma cell malignancy with a highly variable range of clinical manifestations. Over recent decades, substantial progress has been made in laboratory diagnostics, which has deepened our understanding of disease biology ...
Portuguese Multiple Myeloma Grp, Sousa, Maria José Rego de   +1 more
core   +1 more source

Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma

Nature Communications
Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood.
Jiye Liu, Lijie Xing, Jiang Li, Kenneth Wen, Ning Liu, Yuntong Liu, Gongwei Wu, Su Wang, Daisuke Ogiya, Tian-Yu Song, Keiji Kurata, Johany Penailillo, Eugenio Morelli, Tingjian Wang, Xiaoning Hong, Annamaria Gulla, Yu-Tzu Tai, Nikhil Munshi, Paul Richardson, Ruben Carrasco, Teru Hideshima, Kenneth C. Anderson   +21 more
doaj   +1 more source

Decoding IGLL5 Mutation‐Mediated BCR Signaling: A Novel Mechanism of CD8+ T Cell Exhaustion and Ocular MALT Lymphoma Progression

Advanced Science, EarlyView.
OAML harbors recurrent IGLL5 mutations that reinforce CD79A/CD79B‐associated BCR signaling. Mechanistic analysis of the S47G and A54G variants reveals induction of CXCL10/CXCL11, enhanced CD8+ T‐cell recruitment, and exhaustion‐associated dysfunction, supporting an immune‐tolerant niche.
Andi Zhao, Haoyu Wei, Chenyu Zhou, Xinping Sun, Shuyan Da, Haiyu Liu, Zijin Wang, Hui Zhu, Shiya Shen, Qing Shao, Qi Gong, Hu Liu, Xuejuan Chen   +12 more
wiley   +1 more source

Investigation of the intrinsic mechanism of drug resistance in multiple myeloma [PDF]

, 2011
The focus of this thesis was to evaluate the mechanisms whereby myeloma cells develop intrinsic resistance with a focus on resistance in the context of bortezomib treatment.
Ooi, Melissa
core  

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. [PDF]

Multiple myeloma is a treatable, but currently incurable, hematological malignancy of plasma cells characterized by diverse and complex tumor genetics for which precision medicine approaches to treatment are lacking.
Cho, Hearn Jay, Jewell, Scott, DeRome, Mary, Donnelly, Andrea, Christofferson, Austin W., Aldrich, Jessica, Nasser, Sara, Boateng, Martin, Carpten, John, Rohrer, Daniel, Cho, Hearn, Orloff, Gregory, Cuyugan, Lori, Auclair, Daniel, Livermore, Brianne, McBride, Kyle, Jakubowiak, Andrzej, Helland, Adrienne, Reiman, Rebecca, Stumph, Jennifer, Anderson, Kenneth, Wolf, Jeffrey, Jagannath, Sundar, Usmani, Saad Z., Turner, Bryce, Liang, Winnie, Berdeja, Jesus, Skerget, Sheri, Stephenson, Kristi, Kidd, Pam, Adkins, Jonathan R., Vij, Ravi, Miller, Chase, Keats, Jonathan J., Niesvizky, Ruben, Anderson, Kenneth C., Usmani, Saad, Adkins, Jonathan, Aldrich, Jessica L., Kyman, Shari, DAgostino, Mattia, Jakubowiak, Andrzej J., Keats, Jonathan, Chari, Ajai, Kirchhoff, Meghan, Liang, Winnie S., Benard, Brooks, Kurdoglu, Ahmet, Tassone, Erica, Berdeja, Jesús G., D’Agostino, Mattia, Christofferson, Austin, Yellapantula, Venkata, Collison, Kimberly, Zaugg, Barbara, Siegel, David S., Jewell, Scott D., Lonial, Sagar, Levy, Moshe, Gutierrez, Norma, Legendre, Christophe, Gamella, Manuela, Penaherrera, Daniel, Toone, Maureen, McDonald, Jackie, Siegel, David, Washington, Megan, Rohrer, Daniel C., Rogers, Jennifer, Gutiérrez, Norma Carmen, Blanski, Alex, Craig, David, Liles, Darla   +72 more
core   +1 more source

CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide

Nature Communications, 2020
CD229 is expressed on the surface of multiple myeloma cells, as well as B and T lymphocytes. Here, the authors engineer CD229-specific CAR T cells and, using patient samples and mouse models, show that treatment with these cells reduces tumour burden and
Sabarinath V. Radhakrishnan, Tim Luetkens, Sandra D. Scherer, Patricia Davis, Erica R. Vander Mause, Michael L. Olson, Sara Yousef, Jens Panse, Yasmina Abdiche, K. David Li, Rodney R. Miles, William Matsui, Alana L. Welm, Djordje Atanackovic   +13 more
doaj   +1 more source

BCMA‐Engineered Dendritic Cell‐Derived Exosomes as Bi‐Functional Therapeutics Orchestrating Cytokine Sequestration and Immune Activation for Multiple Myeloma

Advanced Science, EarlyView.
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng, Chao He, Zhibin He, Hongbo Chen, Fang Cheng, Yongjiang Zheng   +5 more
wiley   +1 more source

A Humanized Anti‐gD Broadly Neutralizing Antibody Confers Complete Post‐Exposure Protection against Pseudorabies Virus

Advanced Science, EarlyView.
Pseudorabies virus (PRV), an emerging zoonotic α‐herpesvirus, causes life‐threatening human encephalitis. We identified a broad‐spectrum neutralizing antibody 6F7 targeting PRV gD. It blocks gD‐Nectin‐1 binding and membrane fusion, inhibiting replication across all PRV variants, representing a promising candidate for anti‐PRV therapy.
Yue Sun, Jianbo Liu, Shi‐Jia Xu, Meng‐Xin Wang, Hongliang Zhang, Yanhe Zhang, Zhi‐Jun Tian, Jin‐Mei Peng, Xin Yin, Tong‐Qing An, Xue‐Hui Cai, Yan‐Dong Tang   +11 more
wiley   +1 more source

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

Frontiers in Immunology, 2018
The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM ...
Shih-Feng Cho, Shih-Feng Cho, Shih-Feng Cho, Shih-Feng Cho, Kenneth C. Anderson, Kenneth C. Anderson, Yu-Tzu Tai, Yu-Tzu Tai   +7 more
doaj   +1 more source

NAT10‐Mediated ac4C Modification of circANKRD12 Reprograms the Tumor Microenvironment

Advanced Science, EarlyView.
NAT10‐dependent acetylation of circANKRD12 drives translation of the circANKRD12_354aa protein, which binds HDAC2 to stabilize c‐Myc via deubiquitination, promoting multiple myeloma (MM) cell proliferation. Concurrently, the circANKRD12‐HDAC2 axis suppresses H3ac‐mediated transcription of IFN‐γ, TNF‐α, and GZMB in NK cells, leading to NK cell ...
Jiale Zhang, Hui Shi, Chen Wang, Zihao Liu, Lianxin Zhou, Xinyu Lv, Mengjie Guo, Ye Yang, Chunyan Gu   +8 more
wiley   +1 more source